HPLC Purity vs Assay: What Is the Difference on a COA?

HPLC purity and assay answer different questions. A chromatographic purity result usually describes the relative detector response of the target peak under a defined method. An assay is intended to quantify how much target analyte is present against a qualified reference standard. The same HPLC instrument may be used for both, but the calculation, validation purpose, and interpretation are not automatically the same.

This distinction matters when comparing quotations from raw-material suppliers. A COA that shows “Purity by HPLC: 99.5%” may be useful evidence of chromatographic cleanliness, but it does not by itself account for water, residual solvents, inorganic residue, counter-ions, or compounds that the selected detector does not adequately see.

What HPLC area purity actually measures

In a common area-normalization calculation, the target peak area is divided by the sum of the integrated peak areas and expressed as a percentage. This can be a useful way to monitor related organic substances when the method separates them and the detector responds appropriately. It is not automatically an absolute mass-balance measurement.

Peak area depends on more than the mass present. Detector wavelength, molar response, sample preparation, integration settings, co-elution, reporting thresholds, and the response factors of different impurities can all affect the result. A substance with little or no response at the selected UV wavelength may contribute mass without contributing a proportional peak area.

That is why a buyer should not interpret “99.5% area by HPLC” as a universal statement that exactly 995 mg of every 1,000 mg of powder is the target molecule.

What an assay is intended to measure

An assay procedure is intended to determine the content or strength of the target analyte. It commonly compares the sample response with a qualified reference standard of known assigned value and applies the relevant dilution, potency, moisture, salt, or molecular-form corrections.

ICH Q6A treats assay and impurities as related but separate specification elements. It notes that the same HPLC procedure may sometimes be used for both, but a specific, stability-indicating assay should determine content while impurity procedures quantify specified, unspecified, and total impurities as appropriate. The US FDA likewise describes analytical procedures as supporting identity, strength, quality, purity, and potency—distinct attributes that should not be collapsed into one number.

As-is, dry-basis, and anhydrous results

The calculation basis can materially change the reported result:

• As-is or as-received: the result applies to the material in its current condition, including its measured moisture and volatile content.
• Dry basis: the result is mathematically corrected to exclude measured water. It can look higher than the as-is value even though the physical batch has not changed.
• Anhydrous or solvent-free basis: the correction may exclude water and, depending on the specification, specified volatile solvents. The exact definition must be stated rather than assumed.

For salts and hydrates, buyers should also confirm whether the specification refers to the complete salt/hydrate, the free base or free acid equivalent, or the active moiety. Comparing two supplier numbers without aligning these bases can create a false difference—or hide a real one.

Why one chromatogram cannot cover every quality attribute

A robust specification uses complementary tests because no single chromatographic result establishes every aspect of identity and quality. Depending on the material and intended use, relevant controls may include:

• identity by a suitably specific technique;
• assay against a qualified reference standard;
• specified, unspecified, and total organic impurities;
• water by Karl Fischer titration or another justified method;
• residual solvents by gas chromatography;
• inorganic or elemental impurities by an appropriate technique;
• microbiological limits where applicable;
• specific rotation or chiral purity for stereochemically defined materials.

ICH Q7 states that an authentic COA should be batch-specific and list each test performed, its acceptance limit, and the numerical result when the test is numerical. It should also identify the material, batch number, release information, and the responsible quality unit.

Eight questions to ask before approving a COA

1. What exactly does the reported number mean? Ask whether it is area normalization, external-standard assay, titration, activity, or another calculation.
2. Which analytical method and detector were used? “HPLC” alone is not enough; request the method reference or a meaningful summary.
3. Was a qualified reference standard used? Confirm its identity, assigned value, traceability, and whether potency corrections were applied.
4. What is the reporting basis? Verify as-is, dry basis, anhydrous basis, solvent-free basis, or active-moiety equivalent.
5. How are impurities quantified? Ask about specified impurities, unknown impurities, total impurities, reporting thresholds, and relative response factors where relevant.
6. What does the main method fail to detect? Review water, solvents, inorganic residue, counter-ions, and weakly responding compounds separately.
7. Did the run meet system-suitability criteria? FDA laboratory guidance emphasizes qualified reference materials and system suitability as evidence that the method performed appropriately for the run.
8. Is the document tied to the physical lot? Match the product name, grade, batch number, manufacture/retest dates, specification, result, and authorized approval.

A practical comparison rule for buyers

Do not rank suppliers by the largest purity percentage until the methods and calculation bases are aligned. A defensible comparison uses the same molecular form, same reporting basis, comparable analytical specificity, transparent impurity limits, and batch-specific supporting data. If those conditions are not met, 99.8% from one supplier may not be analytically equivalent to 99.5% from another.

Official references

• ICH Q6A: Specifications—Test Procedures and Acceptance Criteria
• FDA: Analytical Procedures and Methods Validation for Drugs and Biologics
• ICH Q7: Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients
• FDA: Laboratory Controls—Methods, Reference Standards, and System Suitability

Scope note: these pharmaceutical-quality references provide widely used analytical principles. The applicable legal, compendial, food, supplement, cosmetic, or customer requirements must still be determined for the specific material, intended use, and destination market.

Review a batch with PathGene

PathGene supplies batch-specific COAs for its active-ingredient portfolio. Before placing a bulk order, buyers may request the applicable specification, analytical-method information, sample documentation, and available batch report for technical review. Browse the product catalog or contact our team with the product, grade, destination market, and intended application.